Related Experiment Video

Updated: Apr 30, 2026

Experimental Metastasis Assay
08:28

Experimental Metastasis Assay

Published on: August 24, 2010

20.3K

LXR agonism inhibits metastatic melanoma through activation of ApoE

    Cancer Discovery
    |May 6, 2014
    PubMed

    Insights

    Targeting nuclear hormone receptors effectively halts melanoma progression across various preclinical models, offering a promising therapeutic strategy for this aggressive skin cancer.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Endocrinology

    Background:

    • Melanoma is an aggressive skin cancer with limited treatment options.
    • Nuclear hormone receptors play roles in cellular processes, including cancer development.

    Purpose of the Study:

    • To investigate the efficacy of targeting nuclear hormone receptors in preclinical melanoma models.
    • To determine if this approach can suppress melanoma progression.

    Main Methods:

    • Utilized diverse preclinical melanoma models.
    • Employed strategies to target nuclear hormone receptors.

    Main Results:

    • Nuclear hormone receptor targeting significantly suppressed melanoma progression.
    • The observed effects were consistent across different preclinical models.

    Conclusions:

    • Targeting nuclear hormone receptors is a viable strategy for suppressing melanoma progression.
    • This approach shows potential for future melanoma therapies.

    More Related Videos

    A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis07:41

    A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

    Published on: March 8, 2022

    2.3K
    A 3D Organotypic Melanoma Spheroid Skin Model08:49

    A 3D Organotypic Melanoma Spheroid Skin Model

    Published on: May 18, 2018

    18.1K

    Related Concept Videos

    The Intrinsic Apoptotic Pathway01:31

    The Intrinsic Apoptotic Pathway

    Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
    6.2K
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    81
    Drug-Receptor Interaction: Agonist01:25

    Drug-Receptor Interaction: Agonist

    Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
    Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
    4.3K